Northwire Canada EditionSunday, July 12, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
M&A / Property Routine +

The Quiet Shift Replacing Million-Dollar Heart Scanners With Software

VentriPoint Expands Global Footprint Amidst Persistent Dilution Concerns

By The Northwire Desk — AI Analysis Apr 16, 2026 · 09:00 VPT · 0.1 VentriPoint Diagnostics Ltd.
Executive Summary
  • VentriPoint Diagnostics (VPT) announced a partnership with the Montecristo Group to deploy its VMS+ AI cardiac imaging platform across Costa Rica's public and private hospital networks.
  • The collaboration focuses on remote screening for congenital and structural heart disease via the Metropolitano Research Institute.
  • This follows previous expansions in Canada (First Light Health) and Northern California (LG Consulting Solutions).
  • The news release also contextualizes VPT against peers like GE HealthCare, Intuitive Surgical, and Johnson & Johnson regarding cardiac care advancements.
  • CEO Hugh MacNaught highlighted the partner's commitment to affordable high-quality care as a strategic fit for expansion in Central America.
Material Impact
  • The announcement represents an incremental step in commercialization rather than a fundamental shift in financial status.
  • No revenue figures, contract values, or profitability milestones were disclosed in this release.
  • The partnership aligns with the established "hub-and-spoke" model previously announced for Canada and California, suggesting execution of a known strategy rather than new value creation.
  • Given the company's history of frequent equity financings to fund operations, this news does not alleviate immediate capital needs or cash flow risks.
  • Market reaction is likely muted as the expansion was anticipated following the March 2026 announcements regarding Canada and US deployments.
VPT · Price
Company Overview
  • VentriPoint Diagnostics develops the VMS+ system, an AI-powered cardiac imaging platform that converts standard 2D ultrasound scans into detailed 3D heart models comparable to cardiac MRI.
  • The technology aims to reduce costs and infrastructure requirements for advanced cardiac diagnostics in remote or underserved areas.
  • Flagship Project: VMS+ Platform deployment across public and private hospital networks globally, utilizing a hub-and-spoke model for specialist interpretation.
  • Regulatory Status: FDA cleared (Feb 2025), Health Canada licensed, EU MDR certified; ongoing validation studies at St. Paul's Hospital.
Read the original news release →

More from VentriPoint Diagnostics Ltd.

Jun 26, 2026 · 08:10

AI cardiac imaging startup scaling niche partnerships while navigating a critical $55k cash balance and negative working capital.

M&A / Property Jun 16, 2026 · 09:11

AI cardiac imaging startup scales commercial partnerships but remains cash-constrained and pre-revenue at scale.

Other May 13, 2026 · 09:00

VentriPoint Diagnostics Secures China Regulatory Green Channel and Edison Gold, Yet Dilution Risks Loom

Regulatory Apr 28, 2026 · 08:00

Ventripoint Advances China Entry Amidst Persistent Dilution Concerns

Regulatory Apr 20, 2026 · 08:50

Ventripoint Wins Gold Edison Award But Cash Burn and Dilution Risks Persist

Other Apr 16, 2026 · 11:00

TSXV Venture Exchange Listed Cardiac Imaging Platform

M&A / Property